Literature DB >> 32269712

P27 deletion enhances hematopoiesis by paracrine action of IL22 secreted from bone marrow mesenchymal stem cells.

Ruinan Lu1,2, Qian Wang3, Jianyong Li1, Dengshun Miao4,2.   

Abstract

Previous studies have reported that p27 deletion stimulates the proliferation of bone marrow mesenchymal stem cells (BM-MSCs) and their differentiation into osteoblasts, it also increases bone marrow hematopoietic progenitor cells (HPCs). However, it is unknown whether the enhanced hematopoiesis induced by p27 deficiency was associated with releasing hematopoietic stem cell (HSC) and HPC supporting factors by BM-MSCs. To answer this question, we cultured the BM-MSCs from wild-type (WT) or p27 knockout (KO) mice, analyzed their proliferation, apoptosis and osteogenesis and harvested their conditioned medium (CM); We also cultured the bone marrow cells (BMCs) with normal medium or CM from WT or KO BM-MSCs and analyzed changes of HSCs and HPCs and colony forming cells (CFCs). Our results showed that the proliferation and osteogenic differentiation of BM-MSCs were increased significantly and their apoptosis was reduced significantly in p27 deficient mice. Simultaneously, we demonstrated that the CM from p27 deficient BM-MSCs stimulated the expansion of HSCs/HPCs more dramatically than that from WT BM-MSCs. Five 2-fold up-regulated proteins were identified in the CM from p27 deficient BM-MSCs by protein chip assays, including interleukin-22 (IL-22), transforming growth factor-β type I receptor, tumor necrosis factor-related Apoptosis-inducing ligands, VE-cadherin and vascular endothelial growth factor B. We confirmed that expression of IL22 at both mRNA and protein levels were up-regulated significantly in p27 deficient BM-MSCs. The treatment of IL22 increased the percentages of HSCs and HPCs in BMC cultures and the number of CFCs in the colony formation assay, whereas the increased HSC/HPC expansion induced by the CM derived from p27 deficient BM-MSCs was blocked by the addition of anti-IL22 antibody in a dose dependent manner. We also found that the percentages of IL22R1, Stat3 and p-Stat3-S727 positive HSCs and HPCs were increased significantly in p27 deficient BMCs. Our findings in this study indicate that p27 deficiency stimulates HSC/HPC expansion by increasing secretion of IL22 by BM-MSCs and activating IL22-Stat3 signaling in HSCs and HPCs. AJTR
Copyright © 2020.

Entities:  

Keywords:  IL22-Stat3 signaling; bone marrow mesenchymal stem cells; hematopoietic progenitor cells; hematopoietic stem cells; p27 deficiency

Year:  2020        PMID: 32269712      PMCID: PMC7137050     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  36 in total

1.  Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.

Authors:  Jing Chen; Jieqiong Wang; Lei Lin; Lijun He; Yuanyuan Wu; Li Zhang; Zhengfang Yi; Yihua Chen; Xiufeng Pang; Mingyao Liu
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

Review 2.  The role of STAT3 in leading the crosstalk between human cancers and the immune system.

Authors:  Yu Wang; Yicheng Shen; Sinan Wang; Qiang Shen; Xuan Zhou
Journal:  Cancer Lett       Date:  2017-12-06       Impact factor: 8.679

3.  TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis.

Authors:  L Zamai; P Secchiero; S Pierpaoli; A Bassini; S Papa; E S Alnemri; L Guidotti; M Vitale; G Zauli
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

4.  Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.

Authors:  K Polyak; M H Lee; H Erdjument-Bromage; A Koff; J M Roberts; P Tempst; J Massagué
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).

Authors:  H Kiyokawa; R D Kineman; K O Manova-Todorova; V C Soares; E S Hoffman; M Ono; D Khanam; A C Hayday; L A Frohman; A Koff
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

6.  TRAIL regulates normal erythroid maturation through an ERK-dependent pathway.

Authors:  Paola Secchiero; Elisabetta Melloni; Markku Heikinheimo; Susanna Mannisto; Roberta Di Pietro; Antonio Iacone; Giorgio Zauli
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

7.  Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.

Authors:  Alan M Hanash; Jarrod A Dudakov; Guoqiang Hua; Margaret H O'Connor; Lauren F Young; Natalie V Singer; Mallory L West; Robert R Jenq; Amanda M Holland; Lucy W Kappel; Arnab Ghosh; Jennifer J Tsai; Uttam K Rao; Nury L Yim; Odette M Smith; Enrico Velardi; Elena B Hawryluk; George F Murphy; Chen Liu; Lynette A Fouser; Richard Kolesnick; Bruce R Blazar; Marcel R M van den Brink
Journal:  Immunity       Date:  2012-08-24       Impact factor: 31.745

8.  IL-22 increases the innate immunity of tissues.

Authors:  Kerstin Wolk; Stefanie Kunz; Ellen Witte; Markus Friedrich; Khusru Asadullah; Robert Sabat
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

9.  Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells.

Authors:  K Hattori; S Dias; B Heissig; N R Hackett; D Lyden; M Tateno; D J Hicklin; Z Zhu; L Witte; R G Crystal; M A Moore; S Rafii
Journal:  J Exp Med       Date:  2001-05-07       Impact factor: 14.307

Review 10.  Mesenchymal Stem Cell Benefits Observed in Bone Marrow Failure and Acquired Aplastic Anemia.

Authors:  Vivian Fonseca Gonzaga; Cristiane Valverde Wenceslau; Gustavo Sabino Lisboa; Eduardo Osório Frare; Irina Kerkis
Journal:  Stem Cells Int       Date:  2017-12-03       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.